Financial Questions & Answers

About Cellectis shares

1. On which exchange are the Cellectis shares listed ?
   Cellectis shares are listed on the Alternext market of Euronext Paris under the ticker ALCLS and with the ISIN Code FR0010425595.
   
   
2. When was the company's first day of trading ?
   Share trading started on February 7, 2007
   
   
3. How many outstanding shares does Cellectis have ?
   As of March 8, 2007, 9,194,926 shares were outstanding. This number can be broken down as follows:
   • the 5,076,682 shares which made up the company's stock capital prior to listing.
   • 2,377,526 new shares (including those from exercise of the overallocation option) issued in the course of the company's IPO.
   • 1,738,678 new shares issued on February 16th 2007 via reimbursement of equity notes issued by the company in 2005.
   • 2,040 new shares issued following the exercise of "BSPCE" stock warrants for company founders.
   
   
4. How can I buy Cellectis shares ?
   Cellectis shares can be acquired through any banker or stockbroker.
   
   
5. Does Cellectis pay a dividend to its shareholders ?
   The Company is still loss-making and this will continue to be the case for some years. As such, no dividend payments are scheduled in the short term.
   
   
6. Does the company intend to proceed with a follow-on offering ?
   Cellectis is not planning a follow-on offering in the coming months but has not ruled out this possibility as a way of financing its development in the future.
   
   

About Cellectis' shareholders

1. Who are Cellectis' main investors ?
   Cellectis' main shareholders are a group of venture capital firms (which own around 53% of the capital post-IPO) and the Institut Pasteur (with around 6%). The balance (41%) is owned by the public (23%) and by individuals, including Cellectis' founders and employees (18%).
   
   
2. Are the Companys's main shareholders subject to a lock-up clause?
   Yes, from the date of the IPO, a 9-month lock-up period applies to the lead investors, the Institut Pasteur, the company's Scientific Advisory Board, certain employees and other persons linked to the company, whereas the period is 12 months for the company's managers.
   
   
3. Where did the IPO investors come from?
   The demand for shares can be broken down geographically as follows: 79% from France, 8.5% from the UK, 7% from Scandinavia and 5% from Switzerland and Germany

About Cellectis' corporate governance

1. What is the Company's legal structure?
   The Company is a French "Société Anonyme" (SA) with a Board of Directors.
   
   Cellectis complies with the internal control legislation and its policy abides by principles of good corporate governance.
   As CEO, André Choulika leads the company's management activities. He overseas the commercial policy and the R&D strategy and liaises between the various corporate departments.
   He is assisted in this task by an informal Executive Board, which generates proposals for optimizing both the company's day-to-day affairs and its longer term strategy. In addition to the CEO, this Executive Board includes the VPs for Sales & Marketing, Science, Finance and Administration.
   
   The company has adopted a range of internal audit and quality control procedures (particularly in the accounting and financial areas) with a view to hitting its strategic targets.
   
   COMPANY MANAGEMENT
   
   • André CHOULIKA, CEO
   • David SOURDIVE, VP Sales & Marketing
   • Frédéric PAQUES, VP Science
   • Marc LE BOZEC, VP Financier
   • Delphine JAY, VP Administration
   BOARD OF DIRECTORS
   
   • Christian POLICARD, Chairman
   • André CHOULIKA
   • David SOURDIVE
   • Raffy KAZANDJIAN
   • KAMINVEST (Martin Bitsch)
   • AGF PRIVATE EQUITY (Thierry Laugel)
   • BANKINVEST (Thomas Tscherning)
   • EDMOND DE ROTHSCHILD INVESTMENT PARTNERS (Gilles Nobécourt)
   • INSTITUT PASTEUR (Alain Guédon) censeur
   
   Cellectis has also constituted the following Committees: a Scientific Committee, a Remuneration Committee and a Financial Committee.
   
   SCIENTIFIC COMMITTEE
   
   • Prof. François JACOB, Honorary Chairman
   • Rodney J. ROTHSTEIN, Chairman
   • Bernard DUJON
   • James E. HABER
   • Luis SERRANO
   • Denis POMPON
   • Frederick W. ALT
   REMUNERATION COMMITTEE
   
   • Christian POLICARD, Chairman
   • Raffy KAZANDJIAN
   • AGF PRIVATE EQUITY (T. Laugel)
   FINANCIAL COMMITTEE
   
   • Raffy KAZANDJIAN, Chairman
   • Marc MORTUREUX
   • Thomas TSCHERNING
   • Marc LE BOZEC

About Cellectis' financial communication

1. Does the Company have a website?
   Yes. The website is published in both French and English and can be found at www.cellectis.com.
   
   
2. What is the Company's accounting reporting standard?
   Cellectis publishes its accounts in the French GAAP format.
   
   
3. When does the Company's fiscal year close?
   December 31.
4. Does the Company have a financial calendar available?
   Yes. This calendar is available in the investor's section on the website and will be updated regularly.
   
   
5. How can I be on the Company's information distribution list?
   By registering on the website www.cellectis.com in the investor's section.
   
   
6. Whom can I talk to at the Company for issues concerning investor relations?
   Mr Marc Le Bozec (CFO), in charge of Investor Relations. You can reach him on +33 1 41 83 99 00 and via e-mail at investors@cellectis.com.